Trastuzumab Deruxtecan in Patients with HER2-Mutant Metastatic Non-Small Cell Lung Cancer: Primary Results of DESTINY-Lung02

被引：0
|
作者：
Janne, P. [1 ]
Goto, Y. [2 ]
Kubo, T. [3 ]
Ninomiya, K. [4 ]
Kim, S. -W. [5 ]
Planchard, D. [6 ]
Ahn, M. -J. [7 ]
Smit, E. F. [8 ]
de Langen, A. J. [9 ]
Perol, M. [10 ]
Pons-Tostivint, E. [11 ]
Novello, S. [12 ]
Hayashi, H. [13 ]
Shimizu, J. [14 ]
Kim, D. -W. [15 ]
Pereira, K. [16 ]
Cheng, F. -C. [16 ]
Taguchi, A. [16 ]
Cheng, Y. [16 ]
Goto, K. [17 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Natl Canc Ctr, Tokyo, Japan
[3] Okayama Univ Hosp, Ctr Clin Oncol, Okayama, Japan
[4] Okayama Univ Hosp, Okayama, Japan
[5] Asan Med Ctr, Seoul, South Korea
[6] Gustave Roussy, Villejuif, France
[7] Samsung Med Ctr, Seoul, South Korea
[8] Leiden Univ, Med Ctr, Leiden, Netherlands
[9] Netherlands Canc Inst, Amsterdam, Netherlands
[10] Leon Berard Ctr, Lyon, France
[11] Univ Nantes, Ctr Hosp Univ Nantes, Nantes, France
[12] Univ Turin, Dept Oncol, Azienda Osped Univ San Luigi Gonzaga, Orbassano, Italy
[13] Kindai Univ Hosp, Osaka, Japan
[14] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
[15] Seoul Natl Univ Hosp, Seoul, South Korea
[16] Daiichi Sankyo Inc, Basking Ridge, NJ USA
[17] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
NSCLC; trastuzumab deruxtecan; HER2;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MA13.10
引用
收藏
页码：S148 / S148
页数：1
相关论文
共 50 条
  • [21] Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial
    Smit, Egbert F.
    Felip, Enriqueta
    Uprety, Dipesh
    Nagasaka, Misako
    Nakagawa, Kazuhiko
    Rodriguez, Luis Paz-Ares
    Pacheco, Jose M.
    Li, Bob T.
    Planchard, David
    Baik, Christina
    Goto, Yasushi
    Murakami, Haruyasu
    Saltos, Andreas
    Pereira, Kaline
    Taguchi, Ayumi
    Cheng, Yingkai
    Yan, Qi
    Feng, Wenqin
    Tsuchihashi, Zenta
    Janne, Pasi A.
    LANCET ONCOLOGY, 2024, 25 (04): : 439 - 454
  • [22] Trastuzumab Deruxtecan Monotherapy in Pretreated HER2-overexpressing Nonsquamous Non-Small Cell Lung Cancer: DESTINY-Lung03 Part 1
    Planchard, D.
    Kim, H. R.
    Suksombooncharoen, T.
    Li, R.
    Samol, J.
    Runglodvatana, Y.
    Lee, K. -Y.
    Chang, G. -C.
    Kowalski, D.
    Han, J. -Y.
    Saw, S.
    Huang, Y.
    Sookprasert, A.
    Nakajima, E.
    Alfon, J.
    Chang, Y. -T.
    Yang, J. C. -H.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S46 - S47
  • [23] Metastatic HER2-amplified non-small-cell lung cancer treated with trastuzumab deruxtecan
    Yun, Karen M.
    Bazhenova, Lyudmila
    BMJ CASE REPORTS, 2023, 16 (05)
  • [24] Genomic landscape and efficacy of HER2-targeted therapy in patients with HER2-mutant non-small cell lung cancer
    Han, Yanjie
    Xiong, Yuanyuan
    Lu, Tao
    Chen, Rongrong
    Liu, Yuan
    Tang, Hui
    Geng, Ruixuan
    Wang, Yingyi
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [25] Primary data from DESTINY-Lung01: A phase II trial of trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC)
    Li, B. T.
    Smit, E. F. F.
    Goto, Y.
    Nakagawa, K.
    Udagawa, H.
    Mazieres, J.
    Nagasaka, M.
    Bazhenova, L.
    Saltos, A. N.
    Felip, E.
    Pacheco, J. M.
    Perol, M.
    Paz-Ares, L.
    Saxena, K.
    Shiga, R.
    Cheng, Y.
    Acharyya, S.
    Shahidi, J.
    Planchard, D.
    Janne, P. A.
    ANNALS OF ONCOLOGY, 2021, 32 : S1323 - S1324
  • [26] A potential central nervous system niche for trastuzumab deruxtecan in patients with HER2-expressing non-small cell lung cancer
    Lazaratos, Anna-Maria
    Bian, David J. H.
    Petrecca, Kevin
    Guiot, Marie-Christine
    Dankner, Matthew
    TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (12) : 3824 - 3830
  • [27] Exposure-response (ER) analyses of efficacy and safety of trastuzumab deruxtecan (T-DXd) to inform dosing recommendation in HER2-mutant non-small cell lung cancer (NSCLC)
    Khatri, Amit
    Polhamus, Daniel
    Cobbina, Enoch
    Garcia, Ramon
    Yoder, Todd
    Abutarif, Malaz
    Garimella, Tushar
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [28] A Case of Metastatic HER2-Amplified Non-Small-Cell Lung Cancer (NSCLC) Treated with Trastuzumab Deruxtecan
    Yun, K.
    Bazhenova, L.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : E38 - E38
  • [29] Trastuzumab Deruxtecan in Non-Small-Cell Lung Cancer
    Tjong, Michael C.
    Mak, Raymond H.
    Louie, Alexander V.
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (18): : 1770 - 1770
  • [30] HER2 exon 20 mutant non-small cell lung cancer with complete remission of intracranial metastases with trastuzumab deruxtecan: a case report
    Guren, Ali Kaan
    Kocaaslan, Erkam
    Agyol, Yesim
    Majidova, Nargiz
    Sever, Nadiye
    Erel, Pinar
    Celebi, Abdussamet
    Arikan, Rukiye
    Isik, Selver
    Sari, Murat
    Bayoglu, Ibrahim Vedat
    Koestek, Osman
    ANTI-CANCER DRUGS, 2024, 35 (08) : 769 - 773
12345